New Methodology Increases NAMPT Activity for Treating Several Diseases including Autoimmune Conditions

Nicotinamide phosphoribosyltransferase (NAMPT) is an enzyme that helps to regulate and reprogram cellular metabolism, and control the activity of NAD-dependent enzymes. In particular, NAMPT sets intracellular NAD levels. A decline in NAD levels is associated with many metabolic and age-related diseases. University of Pittsburgh researchers have developed novel methods and materials for increasing NAMPT activity levels to treat hepatosteatosis, insulin resistance syndromes and/or their associated manifestations, obesity, sarcopenia, disorders of inflammation, autoimmune conditions, skin aging, cardiovascular diseases (e.g., heart failure), acute and/or chronic kidney injury, and cognitive decline. These methods may also help reduce the likelihood of developing skin cancer. 

Description

The methods and materials for increasing NAMPT activity can be used to increase NAD+ levels to slow cognitive decline, vision loss, and/or hearing loss as well as to prolong lifespan. Pitt researchers created a critical document that outlines compounds having the ability to increase NAMPT activity within cells and/or within a mammal, and also methods for treating mammals having a condition responsive to an increase of NAMPT activity.

Applications

• Treating Hepatosteatosis, insulin resistance syndromes
• Obesity, sarcopenia, inflammation disorders
• Age-related cognitive decline
• Autoimmune conditions, skin aging, cardiovascular diseases
• Acute or chronic kidney injury, and infertility
• Reducing the likelihood of developing skin cancer

Advantages

• Compounds can increase NAMPT activity within cells and/or within a mammal
• Humans having various conditions including cardiovascular disease show improvement with increase of NAMPT activity

Invention Readiness

In vitro

IP Status

https://patents.google.com/patent/US20230310424A1

Quick Facts:
Reference Number
05563
Technology Type
Therapeutic Modality
Technology Subtype
Small Molecule
Therapeutic Areas
OncologyEndocrinology and Metabolic Diseases
Therapeutic Indications
Obesity
Lead Inventor
Beibei Chen
Department
Med-Medicine
All Tech Innovators
Beibei ChenToren FinkelYuan Liu
Technology Readiness Level
2. Initial proof of concept, in-vitro
Date Submitted
2020-11-23
Collections
Cardiometabolic